GMAB analyst estimates
Genmab (GMAB) analyst ratings, the average price target and its range, and every firm's latest call.
GMAB analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 29, 2026 | H.C. Wainwright | Genmab price target raised to $70 from $50 at H.C. Wainwright | $70.00 |
| Oct 20, 2026 | Morgan Stanley | Morgan Stanley Assumes Genmab A/S (GMAB) at Equalweight | $42.00 |
| Oct 7, 2026 | Guggenheim | Genmab price target raised to $58 from $54 at Guggenheim | $58.00 |
| Oct 5, 2026 | Guggenheim | Genmab A/S (GMAB) PT Raised to $54 at Guggenheim | $54.00 |
| Jul 22, 2026 | New Street | TD Cowen Upgrades Genmab A/S (GMAB) to Buy | $43.00 |
| May 27, 2026 | Truist Financial | Truist Securities Assumes Genmab A/S (GMAB) at Buy | $40.00 |
| Apr 30, 2026 | H.C. Wainwright | Genmab price target lowered to $38 from $40 at H.C. Wainwright | $38.00 |
| Mar 26, 2026 | Wolfe Research | Genmab initiated with an Outperform at Wolfe Research | $32.00 |
| Feb 23, 2026 | Guggenheim | Genmab price target lowered to $40 from $45 at Guggenheim | $40.00 |
| Feb 17, 2026 | Jefferies | Genmab resumed with a Buy at Jefferies | $41.50 |
| Jan 20, 2026 | H.C. Wainwright | Genmab price target lowered to $39 from $41 at H.C. Wainwright | $39.00 |
| Nov 6, 2025 | Truist Financial | Genmab A/S (GMAB) PT Lowered to $48 at Truist Securities | $48.00 |
| Oct 6, 2025 | Truist Financial | Genmab price target raised to $49 from $46 at Truist | $49.00 |
| Oct 2, 2025 | H.C. Wainwright | Genmab price target raised to $40 from $36 at H.C. Wainwright | $40.00 |
| Sep 29, 2025 | Leerink Partners | Genmab price target raised to $34 from $32 at Leerink | $34.00 |
- 11 firms rate GMAB: 10 buy, 0 hold, 1 sell.
- The average price target is $50.60 from 5 analysts, from $40.00 to $70.00.
Updated 2026-11-02 17:53 UTC